GLP1R and diabetes mellitus: However, when patients with DM were grouped according to their chronic anti-hyperglycemic therapy, those already treated with GLP-1 RA and/or SGLT-2i experienced a 30% lower risk of the primary endpoint than DM patients not on this therapy.